DOCSLIB.ORG

A Mutation of Ikbkg Causes Immune Deficiency Without Impairing Degradation of Iκbα

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
A Mutation of Ikbkg Causes Immune Deficiency Without Impairing Degradation of Iκbα A mutation of Ikbkg causes immune deficiency without impairing degradation of IκBα Owen M. Siggsa, Michael Bergera, Philippe Krebsa, Carrie N. Arnolda, Celine Eidenschenka, Christoph Huberb, Elaine Piriea, Nora G. Smarta, Kevin Khovanantha, Yu Xiaa, Gerald McInerneyc, Gunilla B. Karlsson Hedestamc, David Nemazeeb, and Bruce Beutlera,1 Departments of aGenetics and bImmunology, The Scripps Research Institute, La Jolla, CA 92037; and cDepartment of Microbiology, Tumor and Cell Biology, Karolinska Institutet, SE-171 77 Stockholm, Sweden Contributed by Bruce Beutler, December 30, 2009 (sent for review December 17, 2009) Null alleles of the gene encoding NEMO (NF-κB essential modulator) Whatever the combination of pathways affected, immune defi- are lethal in hemizygous mice and men, whereas hypomorphic ciency is a unifying consequence of germline NEMO mutations. alleles typically cause a syndrome of immune deficiency and ecto- But of all of the targets of NEMO and the IKK complex, there is no dermal dysplasia. Here we describe an allele of Ikbkg in mice that consensus of which are most critical for immunity. A great deal has impaired Toll-like receptor signaling, lymph node formation, devel- been learned from conditional mutations of IKKα, IKKβ, and opment of memory and regulatory T cells, and Ig production, but did NEMO, but a full understanding of their physiological function κ α not cause ectodermal dysplasia. Degradation of I B , which is con- has been precluded by the embryonic lethality that occurs in their sidered a primary requirement for NEMO-mediated immune signal- absence. The same may be true of the biochemical functions of ing, occurred normally in response to Toll-like receptor stimulation, NEMO, some of which may occur downstream of pathways yet ERK phosphorylation and NF-κB p65 nuclear translocation were arrested in the absence of NEMO (e.g., p65 translocation or severely impaired. This selective loss of function highlights the immunological importance of NEMO-regulated pathways beyond TPL2 activation). N N – IκBα degradation, and offers a biochemical explanation for rare Here we describe an -ethyl- -nitrosourea (ENU) induced immune deficiencies in man. mutation of Ikbkg in mice that disrupted TLR signaling and conferred susceptibility to viral and bacterial infection. Hemizygous males were IMMUNOLOGY mutagenesis | N-ethyl-nitrosourea | nuclear factor–κB essential fully viable, yet azoospermic, and most lacked inguinal lymph nodes. modulator | p65 | Toll-like receptor Serum Ig concentrations were reduced, whereas memory, regulatory, and natural killer (NK) T cells were fewer in number. In response to κ α F-κB transcription factors orchestrate numerous immuno- TLR stimulation, I B degradation and phosphorylation of the Nlogical and developmental responses (1). Among the recep- MAPK homologue p38 were intact, yet phosphorylation of ERK and tors that trigger their activity are the Toll-like receptors (TLRs), nuclear translocation of p65 were severely diminished. These data the IL-1 receptor family, B and T cell antigen receptors (BCR/ indicate that broad suppression of NEMO-mediated immune sig- TCR), and TNF receptor family members, including the lym- naling can occur despite IκBα degradation. photoxin β receptor (LTβR), CD40, and ectodysplasin-A receptor (EDAR). NF-κB activity is restrained by members of the IκB Results family, which prevent nuclear translocation of NF-κB subunits. The panr2 Mutation Impairs TLR Signaling and Resistance to Infection. IκB proteins (IκBα,IκBβ, and IκBε) are phosphorylated and Among more than 30,000 third generation (G3) progeny of degraded in response to stimulation, allowing release and nuclear C57BL/6J males mutagenized with ENU, we observed a heritable translocation of NF-κB. IκB phosphorylation is mediated by the phenotype marked by diminished secretion of soluble, bioactive IκB kinase (IKK) complex, which consists of IKK1 (IKKα) and TNF by macrophages stimulated with TLR ligands. This pheno- IKK2 (IKKβ) catalytic subunits, and the regulatory subunit type, designated panr2 (pan-resistance 2), was characterized by an NEMO (IKKγ). impaired response to ligands for TLR3 [poly(I:C)], TLR4 (LPS), IKK activity is also required for phosphorylation of the NF-κB TLR7 (R-848) and TLR9 (CpG oligodeoxynucleotides) and the κ members p105 (NF- B1) and p65 (RelA). Phosphorylated p105 is heterodimers TLR1/2 (Pam3CSK4) and TLR2/6 (MALP-2, pep- polyubiquitinated and degraded in a manner similar to the IκB tidoglycan; Fig. 1). Multiple cytokines were affected, including proteins (2), promoting activation of the TPL2 (tumor progression TNFα, IL-6, IL-12p40, and MCP-1, as well as the inflammatory → locus 2) ERK axis (3, 4). p65 undergoes IKK-dependent mediator NO. Secretion of type 1 IFN in response to TLR3 and fi phosphorylation at serine 536 (5), although the signi cance of this TLR4 stimulation was not affected. panr2 mice were also highly is unclear (1). susceptible to an otherwise sublethal dose of murine cytomega- The range of diseases caused by NEMO mutations highlights lovirus (MCMV; Fig. S1A). Death within 6 d of MCMV infection the physiological importance of NEMO and the IKK complex. was indicative of an innate immune defect, as combined deficiency Null alleles of the X-linked gene encoding NEMO, IKBKG, cause of B and T cells permits survival of a similar infection for more than the inflammatory skin disease incontinentia pigmenti in hetero- 2 weeks (15). Similarly, panr2 mice succumbed to infection with zygous females (6), and are lethal in hemizygous males, as they are Listeria monocytogenes B in mice (7–9). Milder hypomorphic alleles are compatible with within 4 d (Fig. S1 ). viability in males, but cause severe immune deficiency and devel- opmental abnormalities of the teeth, hair, or sweat glands (10). Author contributions: O.M.S. and B.B. designed research; O.M.S., M.B., P.K., C.A., C.E., C. These abnormalities of ectodermal derivatives are thought to H., E.P., K.K., and Y.X. performed research; G.M., G.B.K.H., and D.N. contributed new result from disruption of EDAR signaling, yet there are reports of reagents/analytic tools; O.M.S. and B.B. analyzed data; and O.M.S., N.G.S., and B.B. wrote IKBKG mutations in immune-deficient patients without ecto- the paper. dermal dysplasia (11, 12). Other mutations appear to disrupt The authors declare no conflict of interest. EDAR signaling and CD40-mediated Ig class switching but not 1To whom correspondence should be addressed. E-mail: [email protected]. TLR signaling (13), whereas another mutation disrupts EDAR This article contains supporting information online at www.pnas.org/cgi/content/full/ signaling, but leaves TLR and CD40 signaling largely intact (14). 0915098107/DCSupplemental. www.pnas.org/cgi/doi/10.1073/pnas.0915098107 PNAS Early Edition | 1of6 Downloaded by guest on October 1, 2021 3000 1000 500 wild type panr2 800 400 2000 600 300 (pg/mL) α 400 200 IL-6 (pg/mL) TNF 1000 IL-12p40 (pg/mL) 200 100 ND ND ND ND 0 ND 0 0 4 - 4 N 2 - 4 8 N - 48 -2 :C) K 48 - PS :C) K 4 LPS GN P LPS I S 8 L (I G P-2 CSK CpG P C CpG PG y CS CpG P L 3 R-8 3 R- ALP 3 R-8 A poly(I:C)m MAL poly( M pol m M am a Pa P P 800 100 4000 Fig. 1. The panr2 mutation impairs TLR- 80 induced cytokine secretion. Thioglycollate- 600 3000 elicited peritoneal macrophages from WT (n = nits) /mL) u 12) and panr2 (n =6)micewerestimulated g 60 M) 400 μ 2000 with TLR ligands, and TNFα,IL-6,IL-12p40,and IFN ( IFN -1 (p 1 NO ( 40 MCP-1 concentrations were calculated by e MCP ELISA. NO was measured by Griess assay, and yp 200 t 1000 20 type I IFN was measured by bioassay. Ligand concentrations were as follows: LPS (800 pg/ 0 0 0 mL), poly(I:C) (60 μg/mL), Pam3CSK4 (100 ng/ S ) 4 8 G 2 - S ) 4 G - S 4 G N 2 - μ P C K p - P P K p mL), R-848 (40 ng/mL), CpG (1 M), peptido- L I: P L I:C GN P-2 L I:C) S G P- CS C PGN L CSK Cp P L C C P L 3 R-84 A 3 R-848 A 3 R-848 A μ poly( M poly( M poly( M glycan (PGN,2 g/mL), MALP-2 (20 ng/mL). am P Pam Pam ND, not detected. Bars indicate mean and SE. panr2 Mice Have a Mutation in Ikbkg. Given the broad suppression a T-to-C transition at position 473 of Ikbkg cDNA, in exon 4 of a of NF-κB–dependent cytokine secretion (TNFα, IL-6, IL-12p40, total of 10, leading to a leucine to proline substitution at residue MCP-1), along with normal secretion of an IRF3-dependent 153 (L153P). The affected amino acid lay within the first coiled- cytokine (type 1 IFN), we sequenced the coding exons and splice coil domain of NEMO (Fig. 2D), and did not alter protein junction of five genes known to be required exclusively for TLR- expression or electrophoretic mobility in macrophage lysates (Fig. induced activation of NF-κB(Traf6, Tak1, Ikbkg, Chuk, Ikbkb). Of 2C). Consistent with the chromosomal location of Ikbkg, the panr2 a total of 26,246 target nucleotides, 21,056 (80.2%) were covered phenotype was inherited in an X-linked recessive manner. by high-quality reads in both wild type and mutant templates, and a Unlike Ikbkg knockout mice, panr2 hemizygoteswereviableand single mutation was identified in Ikbkg (Fig. 2A). The mutation was born at Mendelian ratios (Fig. 2B). Conditional deletion of Ikbkg is A C57BL/6J panr2 B male female Ikbkg : +/Y panr2/Y total +/+ +/panr2 total 13 14 27 14 15 29 C Ikbkg+/Y Ikbkg panr2/Y NEMO β-tubulin D IKK binding oligomerization/ubiquitin binding αH1 CC1 αH2 CC2 LZ Pro-rich ZF 63 194 249 278 312 339 389 410 dimerization L153P E Ikbkg+/Y Ikbkgpanr2/Y F 100 Ikbkg+/ Y (n=12) ) Ikbkg panr2/Y (n=8) g 80 m ( t gh i 60 40X we s i t s 40 e Fig.
Load more

Recommended publications
  • Gene Essentiality Landscape and Druggable Oncogenic Dependencies in Herpesviral Primary Effusion Lymphoma
    ARTICLE DOI: 10.1038/s41467-018-05506-9 OPEN Gene essentiality landscape and druggable oncogenic dependencies in herpesviral primary effusion lymphoma Mark Manzano1, Ajinkya Patil1, Alexander Waldrop2, Sandeep S. Dave2, Amir Behdad3 & Eva Gottwein1 Primary effusion lymphoma (PEL) is caused by Kaposi’s sarcoma-associated herpesvirus. Our understanding of PEL is poor and therefore treatment strategies are lacking. To address this 1234567890():,; need, we conducted genome-wide CRISPR/Cas9 knockout screens in eight PEL cell lines. Integration with data from unrelated cancers identifies 210 genes as PEL-specific oncogenic dependencies. Genetic requirements of PEL cell lines are largely independent of Epstein-Barr virus co-infection. Genes of the NF-κB pathway are individually non-essential. Instead, we demonstrate requirements for IRF4 and MDM2. PEL cell lines depend on cellular cyclin D2 and c-FLIP despite expression of viral homologs. Moreover, PEL cell lines are addicted to high levels of MCL1 expression, which are also evident in PEL tumors. Strong dependencies on cyclin D2 and MCL1 render PEL cell lines highly sensitive to palbociclib and S63845. In summary, this work comprehensively identifies genetic dependencies in PEL cell lines and identifies novel strategies for therapeutic intervention. 1 Department of Microbiology-Immunology, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA. 2 Duke Cancer Institute and Center for Genomic and Computational Biology, Duke University, Durham, NC 27708, USA. 3 Department of Pathology, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA. Correspondence and requests for materials should be addressed to E.G. (email: [email protected]) NATURE COMMUNICATIONS | (2018) 9:3263 | DOI: 10.1038/s41467-018-05506-9 | www.nature.com/naturecommunications 1 ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/s41467-018-05506-9 he human oncogenic γ-herpesvirus Kaposi’s sarcoma- (IRF4), a critical oncogene in multiple myeloma33.
    [Show full text]
  • Price List for Out-Of-State Patients (Jul 2017 – Dec 2017)
    Department of Diagnostic Genomics QEII Medical Centre PRICE LIST FOR OUT-OF-STATE PATIENTS (JUL 2017 – DEC 2017) What methods of testing do we employ? Available Methods PCR and/or Sanger DNA Sequencing for predictive testing and familial cascade screening. Targeted Massive Parallel Sequencing (MPS) panels and Sanger sequencing to analyse large genes. MLPA to detect larger deletions and duplications. MS-MLPA to detect methylation changes in addition to deletions and duplications. If you are unsure which method is appropriate for your patient, please contact us by phone on 08 6383 4223 or email on [email protected]. Who do we accept testing requests from? Requesting Clinicians Diagnostic testing can only be requested by a suitably qualified clinician – we do not provide a service direct to the public. For some tests, we will only accept requests once the patient has undergone genetic counselling from a recognised genetic counsellor, due to the clinical sensitivity of these tests. What types of sample(s) are required for testing? Sample requirements for each test are listed below. EDTA Samples Most tests will require a single 2-4mls sample of blood collected with an EDTA preservative. EDTA samples must arrive at our lab within 5 days of phlebotomy, and must be sent at room temperature. Tissue 10-50mg of tissue is required for DNA extraction DNA 1-5µg of extracted DNA (depending on test request) in place of EDTA blood Predictive Testing We recommend testing two separate EDTA blood samples collected from the patient at least 10 minutes apart. Familial Cancer and We recommend testing a second EDTA blood sample in cases where a pathogenic variant is found.
    [Show full text]
  • Core Lab Brochure
    CHOOSE THE MOST TRUSTED LONG-READ TECHNOLOGY FOR YOUR CORE Sequence with Confidence The Sequel® II and IIe Systems are powered by Single Molecule, Real-Time (SMRT®) Sequencing, a technology proven to produce highly accurate long reads, known as HiFi reads, for sequencing data you and your customers can trust. SMRT SEQUENCING IS SMART BUSINESS HiFi Reads: PacBio is the only sequencing technology to offer highly accurate long reads. Because HiFi reads are extremely accurate, downstream analysis is simplified and streamlined, requiring less compute time than the error-prone long reads of other technologies. High Throughput: The Sequel II and IIe Systems have high data yields on robust, highly automated platforms to increase productivity and reduce project costs. Efficient and Easy-To-Use Workflows: Our end-to-end solutions feature library preparation in <3 hours and many push- button analysis workflows, so you can run projects quickly and easily. Support: All of our products are backed by a global team of scientists, bioinformaticians, and engineers who stand ready to provide you with outstanding service. OUTSTANDING PERFORMANCE AND RELIABILITY 99% of runs on the Sequel II System completed successfully Sequel II Systems provide reliable performance with the total bases produced by the PacBio fleet steadily increasing, and 99% of runs completed successfully. “In our experience, the Sequel II System was essentially production-ready right out of the box. We have used it for a range of applications and sample types — from human genome sequencing to metagenome and microbiome profiling to non-model plant and animal genomes — and results have been very good.” — Luke Tallon, Director of the Genomics Resource Center at Maryland Genomics pacb.com/Sequel SMRT SEQUENCING APPLICATIONS – EFFICIENT AND COST EFFECTIVE The Sequel II and IIe Systems support a wide range of applications, each adding unique value to a sequencing study.
    [Show full text]
  • Dimerization of Ltβr by Ltα1β2 Is Necessary and Sufficient for Signal
    Dimerization of LTβRbyLTα1β2 is necessary and sufficient for signal transduction Jawahar Sudhamsua,1, JianPing Yina,1, Eugene Y. Chiangb, Melissa A. Starovasnika, Jane L. Groganb,2, and Sarah G. Hymowitza,2 Departments of aStructural Biology and bImmunology, Genentech, Inc., South San Francisco, CA 94080 Edited by K. Christopher Garcia, Stanford University, Stanford, CA, and approved October 24, 2013 (received for review June 6, 2013) Homotrimeric TNF superfamily ligands signal by inducing trimers survival in a xenogeneic human T-cell–dependent mouse model of of their cognate receptors. As a biologically active heterotrimer, graft-versus-host disease (GVHD) (11). Lymphotoxin(LT)α1β2 is unique in the TNF superfamily. How the TNFRSF members are typically activated by TNFSF-induced three unique potential receptor-binding interfaces in LTα1β2 trig- trimerization or higher order oligomerization, resulting in initiation ger signaling via LTβ Receptor (LTβR) resulting in lymphoid organ- of intracellular signaling processes including the canonical and ogenesis and propagation of inflammatory signals is poorly noncanonical NF-κB pathways (2, 3). Ligand–receptor interactions α β understood. Here we show that LT 1 2 possesses two binding induce higher order assemblies formed between adaptor motifs in sites for LTβR with distinct affinities and that dimerization of LTβR the cytoplasmic regions of the receptors such as death domains or α β fi by LT 1 2 is necessary and suf cient for signal transduction. The TRAF-binding motifs and downstream signaling components such α β β crystal structure of a complex formed by LT 1 2,LT R, and the fab as Fas-associated protein with death domain (FADD), TNFR1- fragment of an antibody that blocks LTβR activation reveals the associated protein with death domain (TRADD), and TNFR-as- lower affinity receptor-binding site.
    [Show full text]
  • OSCAR Is a Receptor for Surfactant Protein D That Activates TNF- Α Release from Human CCR2 + Inflammatory Monocytes
    OSCAR Is a Receptor for Surfactant Protein D That Activates TNF- α Release from Human CCR2 + Inflammatory Monocytes This information is current as Alexander D. Barrow, Yaseelan Palarasah, Mattia Bugatti, of September 25, 2021. Alex S. Holehouse, Derek E. Byers, Michael J. Holtzman, William Vermi, Karsten Skjødt, Erika Crouch and Marco Colonna J Immunol 2015; 194:3317-3326; Prepublished online 25 February 2015; Downloaded from doi: 10.4049/jimmunol.1402289 http://www.jimmunol.org/content/194/7/3317 Supplementary http://www.jimmunol.org/content/suppl/2015/02/24/jimmunol.140228 http://www.jimmunol.org/ Material 9.DCSupplemental References This article cites 40 articles, 10 of which you can access for free at: http://www.jimmunol.org/content/194/7/3317.full#ref-list-1 Why The JI? Submit online. by guest on September 25, 2021 • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2015 by The American Association of Immunologists, Inc. All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. The Journal of Immunology OSCAR Is a Receptor for Surfactant Protein D That Activates TNF-a Release from Human CCR2+ Inflammatory Monocytes Alexander D.
    [Show full text]
  • Profiling Data
    Compound Name DiscoveRx Gene Symbol Entrez Gene Percent Compound Symbol Control Concentration (nM) JNK-IN-8 AAK1 AAK1 69 1000 JNK-IN-8 ABL1(E255K)-phosphorylated ABL1 100 1000 JNK-IN-8 ABL1(F317I)-nonphosphorylated ABL1 87 1000 JNK-IN-8 ABL1(F317I)-phosphorylated ABL1 100 1000 JNK-IN-8 ABL1(F317L)-nonphosphorylated ABL1 65 1000 JNK-IN-8 ABL1(F317L)-phosphorylated ABL1 61 1000 JNK-IN-8 ABL1(H396P)-nonphosphorylated ABL1 42 1000 JNK-IN-8 ABL1(H396P)-phosphorylated ABL1 60 1000 JNK-IN-8 ABL1(M351T)-phosphorylated ABL1 81 1000 JNK-IN-8 ABL1(Q252H)-nonphosphorylated ABL1 100 1000 JNK-IN-8 ABL1(Q252H)-phosphorylated ABL1 56 1000 JNK-IN-8 ABL1(T315I)-nonphosphorylated ABL1 100 1000 JNK-IN-8 ABL1(T315I)-phosphorylated ABL1 92 1000 JNK-IN-8 ABL1(Y253F)-phosphorylated ABL1 71 1000 JNK-IN-8 ABL1-nonphosphorylated ABL1 97 1000 JNK-IN-8 ABL1-phosphorylated ABL1 100 1000 JNK-IN-8 ABL2 ABL2 97 1000 JNK-IN-8 ACVR1 ACVR1 100 1000 JNK-IN-8 ACVR1B ACVR1B 88 1000 JNK-IN-8 ACVR2A ACVR2A 100 1000 JNK-IN-8 ACVR2B ACVR2B 100 1000 JNK-IN-8 ACVRL1 ACVRL1 96 1000 JNK-IN-8 ADCK3 CABC1 100 1000 JNK-IN-8 ADCK4 ADCK4 93 1000 JNK-IN-8 AKT1 AKT1 100 1000 JNK-IN-8 AKT2 AKT2 100 1000 JNK-IN-8 AKT3 AKT3 100 1000 JNK-IN-8 ALK ALK 85 1000 JNK-IN-8 AMPK-alpha1 PRKAA1 100 1000 JNK-IN-8 AMPK-alpha2 PRKAA2 84 1000 JNK-IN-8 ANKK1 ANKK1 75 1000 JNK-IN-8 ARK5 NUAK1 100 1000 JNK-IN-8 ASK1 MAP3K5 100 1000 JNK-IN-8 ASK2 MAP3K6 93 1000 JNK-IN-8 AURKA AURKA 100 1000 JNK-IN-8 AURKA AURKA 84 1000 JNK-IN-8 AURKB AURKB 83 1000 JNK-IN-8 AURKB AURKB 96 1000 JNK-IN-8 AURKC AURKC 95 1000 JNK-IN-8
    [Show full text]
  • Anti-IRAK4 Antibody (ARG54631)
    Product datasheet [email protected] ARG54631 Package: 50 μg anti-IRAK4 antibody Store at: -20°C Summary Product Description Rabbit Polyclonal antibody recognizes IRAK4 Tested Reactivity Hu Tested Application ICC/IF, WB Specificity This antibody specifically recognizeshuman IRAK-4 (IL-1 ReceptorAssociated Kinase-4). This antibodydoes not cross-react with other IRAKs. Host Rabbit Clonality Polyclonal Isotype IgG Target Name IRAK4 Antigen Species Human Immunogen A synthetic peptidecorresponding to amino acids at thecarboxy terminus of human IRAK-4. Conjugation Un-conjugated Alternate Names REN64; Renal carcinoma antigen NY-REN-64; NY-REN-64; Interleukin-1 receptor-associated kinase 4; EC 2.7.11.1; IRAK-4; IPD1 Application Instructions Application table Application Dilution ICC/IF Assay-dependent WB Assay-dependent Application Note * The dilutions indicate recommended starting dilutions and the optimal dilutions or concentrations should be determined by the scientist. Positive Control HeLa and K562 Calculated Mw 52 kDa Properties Form Liquid Purification purified by Immunoaffinity chromatography. Buffer PBS (pH 7.4) and 0.02% Sodium azide Preservative 0.02% Sodium azide Storage instruction For continuous use, store undiluted antibody at 2-8°C for up to a week. For long-term storage, aliquot and store at -20°C or below. Storage in frost free freezers is not recommended. Avoid repeated freeze/thaw cycles. Suggest spin the vial prior to opening. The antibody solution should be gently mixed before use. www.arigobio.com 1/3 Note For laboratory research only, not for drug, diagnostic or other use. Bioinformation Database links GeneID: 51135 Human Swiss-port # Q9NWZ3 Human Gene Symbol IRAK4 Gene Full Name interleukin-1 receptor-associated kinase 4 Background IRAK-4 activates the NF-B and MAPKpathways and plays a role in IL-1Rmediated inflammatory responses andinnate immunity.
    [Show full text]
  • Genetic Landscape of Papillary Thyroid Carcinoma and Nuclear Architecture: an Overview Comparing Pediatric and Adult Populations
    cancers Review Genetic Landscape of Papillary Thyroid Carcinoma and Nuclear Architecture: An Overview Comparing Pediatric and Adult Populations 1, 2, 2 3 Aline Rangel-Pozzo y, Luiza Sisdelli y, Maria Isabel V. Cordioli , Fernanda Vaisman , Paola Caria 4,*, Sabine Mai 1,* and Janete M. Cerutti 2 1 Cell Biology, Research Institute of Oncology and Hematology, University of Manitoba, CancerCare Manitoba, Winnipeg, MB R3E 0V9, Canada; [email protected] 2 Genetic Bases of Thyroid Tumors Laboratory, Division of Genetics, Department of Morphology and Genetics, Universidade Federal de São Paulo/EPM, São Paulo, SP 04039-032, Brazil; [email protected] (L.S.); [email protected] (M.I.V.C.); [email protected] (J.M.C.) 3 Instituto Nacional do Câncer, Rio de Janeiro, RJ 22451-000, Brazil; [email protected] 4 Department of Biomedical Sciences, University of Cagliari, 09042 Cagliari, Italy * Correspondence: [email protected] (P.C.); [email protected] (S.M.); Tel.: +1-204-787-2135 (S.M.) These authors contributed equally to this paper. y Received: 29 September 2020; Accepted: 26 October 2020; Published: 27 October 2020 Simple Summary: Papillary thyroid carcinoma (PTC) represents 80–90% of all differentiated thyroid carcinomas. PTC has a high rate of gene fusions and mutations, which can influence clinical and biological behavior in both children and adults. In this review, we focus on the comparison between pediatric and adult PTC, highlighting genetic alterations, telomere-related genomic instability and changes in nuclear organization as novel biomarkers for thyroid cancers. Abstract: Thyroid cancer is a rare malignancy in the pediatric population that is highly associated with disease aggressiveness and advanced disease stages when compared to adult population.
    [Show full text]
  • Supplementary Table 7. Characterization of Human Proteins Involved in the Prostate Cancer Pathway
    Supplementary Table 7. Characterization of human proteins involved in the prostate cancer pathway f Protein UniProt Protein PONDR-FIT MobiDB Location (length) Location (length) Nint ID length (%)b consensus of long disordered of AIBSse a c d (NAIBS) (%) regions BAD, Bcl2-associated Q92934 168 100.00 84.54 1-105 (105) 1-53 (53) 66 agonist of cell death (4/70.8) 122-147 (27) 57-80 (24) 158-168 (11) 100-129 (30) 146-157 (12) CREB5; cyclic AMP- Q02930 508 85.24 75.39 46-59 (14) 66-86 (21) 65 responsive element (7/67.9) 86-393 (308) 99-183 (85) binding protein 5 447-470 (24) 188-358 (171) 479-508 (31) 362-370 (9) 378-406 (29) 421-444 (24) 503-508 (6) CREB1, cyclic AMP- P16220 341 79.47 40.47 1-32 (32) 32-44 (13) 169 responsive element- (7/29.3) 40-50 (11) 89-104 (16) binding protein 1 102-132 (33) 128-145 (18) 138-171 (34) 166-191 (26) 271-285 (15) 265-270 (6) 307-314 (8) 329-341 (13) FOXO1, Forkhead box Q12778 655 78.63 72.82 1-69 (69) 1-32 (32) 68 protein O1 (19/56.9) 74-101 (28) 54-82 (29) 105-160 (56) 88-118 (31) 199-210 (12) 160-172 (13) 229-336 (107) 182-196 (15) 385-450 (66) 216-226 (11) 463-488 (26) 258-280 (23) 498-569 (72) 289-297 (9) 644-655 (12) 306-314 (9) 323-365 (43) 371-388 (18) 301-409 (8) 447-469 (23) 483-517 (35) 528-545 (18) 550-565 (16) 570-592 (23) 605-612 (8) TCF7L1, transcription Q9HCS4 588 77.04 61.90 1-104 (104) 1-46 (46) 4 factor 7 like 1 (16/54.5) 161-183 (23) 53-74 (22) 192-238 (47) 94-135 (42) 316-344 (29) 146-159 (14) 406-512 (107) 191-201 (11) 524-546 (21) 234-252 (19) 274-288 (15) 349-371 (23) 373-383 (11)
    [Show full text]
  • Molecular Classification of Patients with Unexplained Hamartomatous and Hyperplastic Polyposis
    ORIGINAL CONTRIBUTION Molecular Classification of Patients With Unexplained Hamartomatous and Hyperplastic Polyposis Kevin Sweet, MS, CGC Context Significant proportions of patients with hamartomatous polyposis or with Joseph Willis, MD hyperplastic/mixed polyposis remain without specific clinical and molecular diagnosis Xiao-Ping Zhou, MD, PhD or present atypically. Assigning a syndromic diagnosis is important because it guides management, especially surveillance and prophylactic surgery. Carol Gallione, PhD Objective To systematically classify patients with unexplained hamartomatous or hy- Takeshi Sawada, MD, PhD perplastic/mixed polyposis by extensive molecular analysis in the context of central Pia Alhopuro, MD rereview of histopathology results. Sok Kean Khoo, PhD Design, Setting, and Patients Prospective, referral-based study of 49 unrelated patients from outside institutions (n=28) and at a comprehensive cancer center (n=21), Attila Patocs, MD, PhD conducted from May 2, 2002, until December 15, 2004. Germline analysis of PTEN, Cossette Martin, PhD BMPR1A, STK11 (sequence, deletion), SMAD4, and ENG (sequence), specific exon screen- Scott Bridgeman, BSc ing of BRAF, MYH, and BHD, and rereview of polyp histology results were performed. John Heinz, PhD Main Outcome Measures Molecular, clinical, and histopathological findings in pa- tients with unexplained polyposis. Robert Pilarski, MS, CGC Results Of the 49 patients, 11 (22%) had germline mutations. Of 14 patients with Rainer Lehtonen, BSc juvenile polyposis, 2 with early-onset disease had mutations in ENG, encoding endo- Thomas W. Prior, PhD glin, previously only associated with hereditary hemorrhagic telangiectasia; 1 had hemi- zygous deletion encompassing PTEN and BMPR1A; and 1 had an SMAD4 mutation. Thierry Frebourg, MD, PhD One individual previously classified with Peutz-Jeghers syndrome had a PTEN dele- Bin Tean Teh, MD, PhD tion.
    [Show full text]
  • Eda-Activated Relb Recruits an SWI/SNF (BAF) Chromatin-Remodeling Complex and Initiates Gene Transcription in Skin Appendage Formation
    Eda-activated RelB recruits an SWI/SNF (BAF) chromatin-remodeling complex and initiates gene transcription in skin appendage formation Jian Simaa,1,2, Zhijiang Yana,1, Yaohui Chena, Elin Lehrmanna, Yongqing Zhanga, Ramaiah Nagarajaa, Weidong Wanga, Zhong Wangb, and David Schlessingera,2 aLaboratory of Genetics and Genomics, National Institute on Aging/NIH-Intramural Research Program, Baltimore, MD 21224; and bDepartment of Cardiac Surgery, Cardiovascular Research Center, University of Michigan, Ann Arbor, MI 48109 Edited by Elaine Fuchs, The Rockefeller University, New York, NY, and approved June 28, 2018 (received for review January 23, 2018) Ectodysplasin A (Eda) signaling activates NF-κB during skin ap- during organ development induce distinct BAF complexes to pendage formation, but how Eda controls specific gene transcrip- modulate gene expression. tion remains unclear. Here, we find that Eda triggers the formation Here, we report that skin-specific Eda signaling triggers the for- of an NF-κB–associated SWI/SNF (BAF) complex in which p50/RelB re- mation of a large BAF-containing complex that includes a BAF cruits a linker protein, Tfg, that interacts with BAF45d in the BAF com- complex, an NF-κB dimer of p50/RelB, and a specific linker pro- plex. We further reveal that Tfg is initially induced by Eda-mediated tein, Tfg (TRK-fusion gene). Thus, Eda/NF-κB signaling operates RelB activation and then bridges RelB and BAF for subsequent gene through a BAF complex to regulate specific gene expression in regulation. The BAF component BAF250a is particularly up-regulated in organ development, which may exemplify a more general paradigm skin appendages, and epidermal knockout of BAF250a impairs skin for gene-specific regulation in many other systems.
    [Show full text]
  • Inhibition of Mitochondrial Complex II in Neuronal Cells Triggers Unique
    www.nature.com/scientificreports OPEN Inhibition of mitochondrial complex II in neuronal cells triggers unique pathways culminating in autophagy with implications for neurodegeneration Sathyanarayanan Ranganayaki1, Neema Jamshidi2, Mohamad Aiyaz3, Santhosh‑Kumar Rashmi4, Narayanappa Gayathri4, Pulleri Kandi Harsha5, Balasundaram Padmanabhan6 & Muchukunte Mukunda Srinivas Bharath7* Mitochondrial dysfunction and neurodegeneration underlie movement disorders such as Parkinson’s disease, Huntington’s disease and Manganism among others. As a corollary, inhibition of mitochondrial complex I (CI) and complex II (CII) by toxins 1‑methyl‑4‑phenylpyridinium (MPP+) and 3‑nitropropionic acid (3‑NPA) respectively, induced degenerative changes noted in such neurodegenerative diseases. We aimed to unravel the down‑stream pathways associated with CII inhibition and compared with CI inhibition and the Manganese (Mn) neurotoxicity. Genome‑wide transcriptomics of N27 neuronal cells exposed to 3‑NPA, compared with MPP+ and Mn revealed varied transcriptomic profle. Along with mitochondrial and synaptic pathways, Autophagy was the predominant pathway diferentially regulated in the 3‑NPA model with implications for neuronal survival. This pathway was unique to 3‑NPA, as substantiated by in silico modelling of the three toxins. Morphological and biochemical validation of autophagy markers in the cell model of 3‑NPA revealed incomplete autophagy mediated by mechanistic Target of Rapamycin Complex 2 (mTORC2) pathway. Interestingly, Brain Derived Neurotrophic Factor
    [Show full text]